Cervical Cancer Vaccine Market Driven by Rising Demand for Development of Low-cost Vaccines, says TMR

Transparency Market Research (TMR) announces a new report on the global cervical cancer vaccines market. The report presents detailed predictions regarding the growth of the cervical cancer vaccines market in the coming years, based on solid analysis of the market’s present and historical figures. The competitive and regional dynamics of the global cervical cancer vaccines market are also examined in the report, providing readers with a comprehensive overview of the market. The report is titled ‘Cervical Cancer Vaccine Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.’

Cervical cancer is an increasingly prevalent form of cancer and is found in women worldwide. It is closely associated with the human papillomavirus, as up to 99% cases of cervical cancer are accompanied by an HPV infection. Two high-risk types of HPV collectively account for more than 70% of cervical cancer cases in the world. As a result, HPV vaccines have been a key part of cervical cancer treatment and still account for a significant part of the treatment scenario of cervical cancer. Since October 2016, the CDC recommends that all individuals between the ages of 9 and 14 should receive two HPV vaccinations within six months.

The growing prevalence of cervical cancer in developing regions is a key driver for the global cervical cancer vaccines market. This has led to leading players in the global cervical cancer vaccine market trying to maximize their gains by developing low-cost cervical cancer vaccines. The cervical cancer vaccine market has also received stable assistance from government bodies as well as NGOs in recent years due to the rising severity of the problem, which is likely to remain a key driver for the global cervical cancer vaccine market in the coming years. While the high cost of the vaccines has kept them away from a considerable demographic in underdeveloped regions, the growing prevalence of the disease could force key players to boost their research investment in order to establish a firm position in populous markets such as Asia Pacific and Africa.

By vaccine type, the global cervical cancer vaccine market is segmented into bivalent, quadrivalent, and 9-valent vaccines. Currently, the US FDA has only approved three cervical cancer vaccines, namely Cervarix, developed by GlaxoSmithKline, and Gardasil and Gardasil 9, developed by Merck & Co. Inc. Cervarix is a bivalent vaccine targeting two strains of HPV, namely HPV-16 and HPV-18. On the other hand, Gardasil is a quadrivalent vaccine and targets HPV-6 and HPV-11 in addition to HPV-16 and HPV-18.

The strong research and development scenario in the healthcare sector is likely to enable North America’s continued dominance in the global cervical cancer vaccines market in the coming years. The strong collaboration activities between public and private healthcare bodies in the region, united in developing effective vaccines against a range of diseases, is likely to remain a key driver for the cervical cancer vaccine market in North America. Nevertheless, the rising prevalence of cervical cancer in underdeveloped regions and the increasing attention being paid by the WHO to the problem is likely to drive the demand from the cervical cancer vaccine market in Asia Pacific, Africa, and Latin America in the coming years.

Apart from Merck and GlaxoSmithKline, ISA Pharmaceuticals BV is a rising name in the global cervical cancer vaccine market. Success of their immunotherapeutic cervical cancer vaccine, currently in phase II trials, would allow ISA Pharmaceuticals BV to take up a significant share in the global cervical cancer vaccine market in the coming years.

Request to View Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24071